1. A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 24‐week efficacy and safety results from a randomized, double‐blinded trial*. (1st June 2021) Authors: Blauvelt, A.; Leonardi, C.; Elewski, B.; Crowley, J.J.; Guenther, L.C.; Gooderham, M.; Langley, R.G.; Vender, R.; Pinter, A.; Griffiths, C.E.M.; Tada, Y.; Elmaraghy, H.; Lima, R.G.; Gallo, G.; Renda, L.; Burge, R.; Park, S.Y.; Zhu, B.; Papp, K. Journal: British journal of dermatology Issue: Volume 184:Number 6(2021) Page Start: 1047 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 24‐week efficacy and safety results from a randomized, double‐blinded trial. (1st June 2021) Authors: Blauvelt, A.; Leonardi, C.; Elewski, B.; Crowley, J.J.; Guenther, L.C.; Gooderham, M.; Langley, R.G.; Vender, R.; Pinter, A.; Griffiths, C.E.M.; Tada, Y.; Elmaraghy, H.; Lima, R.G.; Gallo, G.; Renda, L.; Burge, R.; Park, S.Y.; Zhu, B.; Papp, K. Journal: British journal of dermatology Issue: Volume 184:Number 6(2021) Page Start: 1047 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 24‐week efficacy and safety results from a randomized, double‐blinded trial. (25th October 2020) Authors: Blauvelt, A.; Leonardi, C.; Elewski, B.; Crowley, J.J.; Guenther, L.C.; Gooderham, M.; Langley, R.G.; Vender, R.; Pinter, A.; Griffiths, C.E.M.; Tada, Y.; Elmaraghy, H.; Lima, R.G.; Gallo, G.; Renda, L.; Burge, R.; Park, S.Y.; Zhu, B.; Papp, K. Journal: British journal of dermatology Issue: Volume 184:Number 6(2021) Page Start: 1047 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. A treatment for severe nodular acne: a randomized investigator‐blinded, controlled, noninferiority trial comparing fixed‐dose adapalene/benzoyl peroxide plus doxycycline vs. oral isotretinoin. (1st December 2014) Authors: Tan, J.; Humphrey, S.; Vender, R.; Barankin, B.; Gooderham, M.; Kerrouche, N.; Audibert, F.; Lynde, C. Journal: British journal of dermatology Issue: Volume 171:Number 6(2014:Dec.) Page Start: 1508 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. A treatment for severe nodular acne: a randomized investigator‐blinded, controlled, noninferiority trial comparing fixed‐dose adapalene/benzoyl peroxide plus doxycycline vs. oral isotretinoin. (28th October 2014) Authors: Tan, J.; Humphrey, S.; Vender, R.; Barankin, B.; Gooderham, M.; Kerrouche, N.; Audibert, F.; Lynde, C.; the POWER study group Journal: British journal of dermatology Issue: Volume 171:Number 6(2014:Dec.) Page Start: 1508 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. AB0759 FOUR-YEAR EFFICACY AND SAFETY OF GUSELKUMAB IN PSORIASIS PATIENTS WITH AND WITHOUT PSORIATIC ARTHRITIS: A POOLED ANALYSIS FROM VOYAGE 1 AND VOYAGE 2. (2nd June 2020) Authors: Reich, K.; Dutz, J.; Foley, P.; Thaçi, D.; Vender, R.; Song, M.; Miller, M.; You, Y.; Li, S.; Shen, Y. K.; Armstrong, A. Journal: Annals of the rheumatic diseases Issue: Volume 79(2020)Supplement 1 Page Start: 1677 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. AB0939 Off-label secukinumab dose escalation in the treatment of moderate-to-severe psoriasis: a multicenter, retrospective study. (12th June 2018) Authors: Phung, M.; Ighani, A.; Georgakopoulos, J.R.; Vender, R.; Giroux, L.; Lansang, P.; Yeung, J. Journal: Annals of the rheumatic diseases Issue: Volume 77(2018)Supplement 2 Page Start: 1594 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Anti‐GM‐CSF therapy in psoriasis. (1st June 2019) Authors: Papp, K.A.; Gooderham, M.; Jenkins, R.; Vender, R.; Szepietowski, J.C.; Wagner, T.; Hunt, B.; Souberbielle, B. Journal: British journal of dermatology Issue: Volume 180:Number 6(2019) Page Start: e234 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Anti‐GM‐CSF therapy in psoriasis. (3rd June 2019) Authors: Papp, K.A.; Gooderham, M.; Jenkins, R.; Vender, R.; Szepietowski, J.C.; Wagner, T.; Hunt, B.; Souberbielle, B. Journal: British journal of dermatology Issue: Volume 180:Number 6(2019) Page Start: e234 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Biosimilars for psoriasis: clinical studies to determine similarity. (1st July 2017) Authors: Blauvelt, A.; Puig, L.; Chimenti, S.; Vender, R.; Rajagopalan, M.; Romiti, R.; Skov, L.; Zachariae, C.; Young, H.; Prens, E.; Cohen, A.; van der Walt, J.; Wu, J.J. Journal: British journal of dermatology Issue: Volume 177:Number 1(2017) Page Start: 23 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗